Anti-infective Agents : Antiretroviral Agents
ONORV2 “Norvir FC tablet” 100 mg /tab
適應症：可和其他抗反轉錄病毒藥物合用，以治療人類免疫缺乏病毒(HIV-1)的感染。
Usual dose:
Ritonavir is recommended only as a pharmacokinetic enhancer of other protease inhibitors when used in low doses (guideline dosing).
Adult: (sole protease inhibitor) initial, 300 mg bid, increase by 100 mg bid every 2 to 3 days up to maintenance dose of 600 mg bid; MAX 600 mg bid (manufacturer dosing).
Pediatric: (sole protease inhibitor) children older than 1 month; initial, 250 mg/m(2) bid, increase by 50 mg/m(2) bid every 2 to 3 days, up to maintenance dose of 350 to 400 mg/m(2) bid; MAX 600 mg bid.
Dose adjustment:
Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; however, ritonavir levels may be decreased in moderate impairment and patient response should be monitored.
Severe impairment (Child-Pugh class C): Not recommended
Contraindication:
Hypersensitivity to ritonavir or any component of the formulation; concurrent alfuzosin, amiodarone, cisapride, dihydroergotamine, ergonovine, ergotamine, flecainide, lovastatin, methylergonovine, midazolam (oral), pimozide, propafenone, quinidine, sildenafil, simvastatin, St John’s wort, triazolam, and voriconazole (when ritonavir ≥800 mg/day), astemizole, bepridil, fusidic acid, methylergonovine, midazolam, rivaroxaban, voriconazole, salmeterol, terfenadine, or vardenafil.
Precaution:
Hypersensitivity reactions, Fat redistribution, Immune reconstitution syndrome, Increased cholesterol, PR interval prolongation.
Adverse effect: flushing, paresthesia, fatigue, dizzines, skin rash, pruritus, hypercholesterolemia, increased serum triglycerides, diarrhea, nausea, vomiting, abdominal pain, dysgeusia, dyspepsia, increased gamma-glutamyl transferase, musculoskeletal pain, weakness, increased creatine phosphokinase, cough, oropharyngeal pain.